Is Sermorelin with ipamorelin legal in Australia?

The combination most likely to arrive from a compounding pharmacy with a prescriber's name on it, usually as a nightly subcutaneous dose. The combination has never been tested. Sermorelin was an approved medicine and the ipamorelin half has one randomised human trial, in 117 post-surgical patients, where it was safe and did not beat placebo on its endpoint.

This is the respectable end of the blend market: a prescriber, a compounding pharmacy, a labelled syringe, an instruction to inject at bedtime five nights a week. That framing carries an implication that something was evaluated.

Mechanism: Sermorelin binds the GHRH receptor on pituitary somatotrophs and increases the amplitude of a growth hormone pulse. Ipamorelin binds the growth hormone secretagogue receptor and triggers a pulse, selected by prescribers for releasing growth hormone with less effect on cortisol and prolactin than the older GHRPs.

Regulatory history: Not approved as a combination. Sermorelin held US approval and was withdrawn from the market for commercial reasons; ipamorelin has never been approved anywhere.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Sermorelin with ipamorelin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.